{"url_path":"/sec/ngne/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1404644/0001404644-26-000056-index.html","accession_number":"0001404644-26-000056","cik":"0001404644","ticker":"NGNE","issuer_name":"Neurogene Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1404644/0001404644-26-000056-index.html","primary_entity_key":"0001404644","primary_entity_name":"Neurogene Inc."},"word_count":172,"has_tables":true,"body_markdown":"Item 2.02Results of Operations and Financial Condition\n\nOn August 11, 2026, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2026. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on August 11, 2026, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.\n\nThe information in this Item 2.02 and Exhibits 99.1 and 99.2 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibits 99.1 and 99.2 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing."}